Actu-Real’s in-depth post hoc analysis of EQ – 5D data assesses the burden of chronic Hepatitis C
Client Need and Challenge
The client needed assistance in analyzing the impact of their product, a direct-acting anti-viral (DAA) in combination with Pegylated Interferon/Ribavirin or PR therapy, on patients with compensated liver disease from a placebo-controlled double-blind clinical trial.
How Did We Help?
Our post-hoc analysis revealed that clinical trial patients exhibited a higher burden of illness at baseline compared to population norms, providing valuable insights to the client.
We supported the client by
- Deriving EQ-5D index from 0 to 1 (poor to good health state) through EQ-5D descriptive and visual analogue scale (VAS) as administered at baseline
- Comparing EQ-5D of subjects against population norms of four generic health-related quality of life indices published from a national health measurement study